Phase II trial results on enzalutamide and paclitaxel in LAR-enriched TNBC

Bora Lim, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides a brief overview on the Phase II trial (NCT02276443) of neoadjuvant enzalutamide and paclitaxel in luminous androgen receptor (LAR)-enriched triple-negative breast cancer (TNBC). A promising response rate was seen in a cohort of 24 patients. The study also sought to understand the biological heterogeneity of TNBC by comparing the RNA sequencing of the LAR subtype to immunohistochemistry (IHC). An IHC of 70% and above was well-matched to the RNA sequencing of the LAR subtype, which can be used as a reference in future studies. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.